Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The UK is seeing a rise in COVID-19 infections ahead of winter, with the XFG variant, also known as Stratus, among the circulating strains.

Cases, hospital admissions and deaths have increased, while flu and respiratory syncytial virus (RSV) are also concerns heading into the colder months.

COVID Cases And Deaths Rise In UK

Latest UK Health Security Agency (UKHSA) data show around 2.46 COVID-19 hospital admissions per 100,000 people each week.

The UK recorded 3,942 confirmed cases in October so far, compared with 4,589 in September and 1,374 in August.

People aged 85 and older remain the most vulnerable, with almost 27 hospital admissions per 100,000 people, more than 10 times the national average. Around 13.5% of this age group tested positive, compared with 8.8% across all age groups.

COVID-19 deaths rose 46.4%, from 28 to 41, in the week ending October 2. Cases increased 13.5% in the week to October 7, according to UKHSA data.

Unusual COVID Symptoms: Red And Itchy Eyes

Also read: XFG Variant In Spain: COVID-19 Cases Rise Amid Respiratory Infection Surge

A persistent cough, fever and sore throat are familiar COVID-19 symptoms. However, eye irritation and conjunctivitis may also signal infection, pharmacist Noel Wicks told The Mirror.

“The COVID-19 virus can enter the body through our eyes where it may cause symptoms.”

Wicks said conjunctivitis, which causes red, irritated and sometimes sticky eyes, can occur even without other COVID-19 symptoms.

“Clinical studies have demonstrated that conjunctivitis (red eye) is present in people who test positive for coronavirus, with rates of conjunctivitis ranging from 2% to over 14%, even if people don’t have any other COVID symptoms. In fact, conjunctivitis can be the first and/or the only symptom of COVID,” he said.

Research involving 6,308 people found that approximately 11% of COVID-19 patients experienced eye symptoms. These included conjunctivitis, dryness, redness, watering and itching.

Signs Of COVID-Related Conjunctivitis

Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France

According to Wicks, symptoms may include:

• Pink or red whites of the eyes
• Sore or inflamed eyelids
• Gritty, itchy eyes
• White or yellow discharge

“These symptoms need to be tackled very quickly,” he said.

There is no established evidence that XFG causes eye symptoms more frequently than other COVID-19 variants. Allergies, bacterial infections and other viruses can also cause eye irritation, so these symptoms alone cannot confirm COVID-19.

How To Manage Eye Irritation

Wicks recommends gently cleaning the eyes, avoiding rubbing them and temporarily stopping contact lens use and eye makeup until symptoms improve.

“Make sure to keep your eyes clean by washing them gently with a clean flannel to remove any crusts. Don’t rub your eyes as this can transfer infection from your hands to your eyes. Remove contact lenses and don’t wear eye makeup until the infection is better,” he advised.

Persistent irritation warrants advice from a healthcare professional. Eye pain, sensitivity to light or changes in vision require urgent medical assessment.

What Is The COVID XFG Variant?

XFG, also known as Stratus, is a recombinant Omicron lineage formed when two Omicron sub-lineages combined. The World Health Organization classified it as a variant under monitoring in 2025 because of its growth advantage.

Although XFG carries mutations in its spike protein, studies suggest its ability to evade immunity differs only slightly from that of other JN.1 descendants.

There is no evidence that XFG causes more severe illness than other circulating Omicron variants. However, increased transmission can still raise hospital admissions by increasing the overall number of infections.

Fatty liver disease, which affects nearly 30% of adults worldwide, may comprise five biologically distinct subtypes, according to new research.

Researchers from the Mayo Clinic and Virginia Tech in the US found that each subtype may carry different risks of liver failure, cancer, heart disease and other serious complications.

The study, published in Nature Communications, suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) can develop through different biological pathways. Some are closely linked to obesity and diabetes, while others appear to be driven by inherited genetic factors.

The findings suggest that genetic forms of the disease may progress to advanced liver damage even in people without typical metabolic risk factors.

Why Fatty Liver Disease Can Be Dangerous

Also read: NAFLD to MASLD: Experts Explain Why This Common Yet Dangerous Liver Condition Got Renamed

MASLD, previously known as nonalcoholic fatty liver disease, develops when excess fat accumulates in the liver. Many people experience no noticeable symptoms, allowing the condition to go undetected for years.

Although the disease does not always cause serious complications, it can progress to inflammation, scarring and permanent liver damage. In advanced cases, it may lead to cirrhosis, in which extensive scarring impairs liver function.

MASLD is a major contributor to cirrhosis, liver cancer and liver transplantation worldwide. Understanding why some patients develop severe complications while others do not is therefore an important research priority.

Genetic Analysis Reveals Five Distinct Subtypes

To investigate the differences, the researchers analyzed genetic sequencing results alongside detailed medical records from more than 4,600 patients with MASLD.

The data included liver enzyme measurements, body mass index, blood lipid levels and other indicators of metabolic health. The researchers also examined coexisting conditions, including diabetes, depression and sleep apnea.

Using computational models, they identified five groups of patients who shared distinct biological characteristics. The findings suggest that people with the same MASLD diagnosis may have different underlying disease processes and risks of complications.

“When clinical and genomic data are analyzed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden,” said Shulan Tian, Ph.D., co-senior author and a bioinformatician at Mayo Clinic. “Once you separate these subtypes, you can start to match treatments to the biology that's actually driving the disease.”

Links to Depression, Sleep Apnea and Migraines

Read More: Lancet Study Shows Metabolic Liver Disease To Rise Over 38% By 2050: What’s Behind The Surge

The findings also suggest that the differences between MASLD subtypes extend beyond the liver.

Researchers identified associations between specific subtypes and conditions such as depression, sleep apnea and migraine. These links suggest that the biological processes underlying some forms of fatty liver disease may also be associated with health problems affecting other parts of the body.

However, the findings do not establish that MASLD directly causes these conditions.

Could the Findings Improve Treatment?

Identifying distinct subtypes could eventually help doctors recognize high-risk patients earlier, improve screening and develop more personalized treatment strategies.

Eric Klee, a research and innovation leader at Mayo Clinic, said the approach could help researchers better understand disease progression and identify opportunities to intervene before severe damage occurs.

The team plans to evaluate the findings in larger and more diverse patient populations and investigate whether the subtypes respond differently to treatments, including GLP-1 receptor agonists.

If further studies validate the results, the research could help move MASLD care toward earlier intervention and treatments tailored to the biological processes driving each patient's disease.

Even as Republicans struggle to win over female voters two weeks before the midterm elections, US President Donald Trump has signed an executive order backed by First Lady Melania Trump to advance the health of women in America.

The initiative will establish a new Division of Women’s Health within the National Institutes of Health (NIH) and a Women’s Health Task Force within the White House.

The executive order aims to advance women’s health by ensuring that medical research, diagnosis, prevention and treatment reflect the highest-quality scientific evidence, to improve health outcomes at every stage of life.

“Our mission must serve women at every stage of life, from young girls just starting out to mothers dealing with a complex range of responsibilities, to mature women who deserve to have vitality, dignity and independence,” the first lady said.

Trump called the announcement “a big deal” and credited himself with introducing a new initiative. “When I heard about it, I said, ‘Are you sure they don’t have that?’” the president said. “Who the hell wouldn’t have a women’s health division?”

Is This the First US Women’s Health Research Initiative?

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

The US has had a dedicated office for women’s health research since 1990, when the Office of Research on Women’s Health was established at the NIH during President George H.W. Bush’s administration.

In April 2025, a few months after Trump took office, the Department of Health and Human Services decided to slash funding for the Women’s Health Initiative, a long-running, taxpayer-funded study of a broad range of women’s health issues that began in the 1990s. Officials restored the funding after a public outcry.

“These studies represent critical contributions to our better understanding of women’s health,” Emily G. Hilliard, a department spokeswoman, said at the time.

The new division will operate in coordination with the existing Office of Research on Women’s Health rather than replace it. Under the order, it must be established within an appropriate NIH institute or center within 90 days.

The White House said the move is intended to broaden the government’s focus beyond research and prioritize translating scientific discoveries into clinical care for women and girls.

What Are Melania Trump’s Five Pillars of Women’s Health Innovation?

Read More: Nearly 4,000 Measles Cases In US: CDC Director Says MMR Vaccine Is ‘Absolutely Safe’

Melania highlighted her “First Lady’s Five Pillars of Women’s Health Innovation,” which outline the initiative’s proposed approach:

1. Direct research funding: Support research aimed at finding cures for conditions that uniquely affect women.
2. Use artificial intelligence: Leverage advanced AI capabilities to improve understanding of female biology and accelerate medical discoveries.
3. Speed up treatment development: Accelerate the transition of promising therapies from laboratories to female patients while maintaining strict safety standards.
4. Improve access and affordability: Ensure medical breakthroughs are accessible and affordable to women, regardless of their financial circumstances.
5. Encourage open conversations: Replace generations of silence with open discussion, education and compassion around women’s health.

The Women’s Health Task Force will work in collaboration with the private sector to advance new technologies and solutions for women’s health.

It aims to develop high-quality, scientifically supported medical information and care while advancing new treatments, therapies and cures for women.

It will be led by White House Chief of Staff Susie Wiles, who recently completed treatment for breast cancer, and Health and Human Services Secretary Robert F. Kennedy Jr.

While Trump said the panel will coordinate with various federal agencies and programs, the executive order does not specify funding targets.

Which Health Conditions Will the New Division Study?

According to the Department of Health and Human Services, the division will study conditions that uniquely or disproportionately affect women, including:

• Cardiovascular disease and cancer
• Autoimmune and inflammatory conditions
• Chronic pain
• Endometriosis and fibroids
• Polycystic ovary syndrome (PCOS)
• Infertility and menopause
• Alzheimer’s disease and osteoporosis.